BRAF inhibitors in melanoma: cutaneous adverse events after 1 year

We have a new paper on the cutaneous adverse events of BRAF inhibitor based therapies in patients with metastatic malignant melanoma.
It is fantastic that patients are surviving more than 1 year with these therapies, but dermatologists and oncologists should be aware that side effects from these medications are still present and need to be managed. We have not found new adverse events, and some are less frequent (such as squamous cell carcinomas in single agent BRAFi); but they do not disappear with time!